Health and Healthcare

Mylan Fires Back at Perrigo

Mylan N.V. (NASDAQ: MYL) announced Tuesday, in conjunction with the Irish Takeover Panel, that Perrigo Co. PLC (NYSE: PRGO) had made misleading statements to shareholders regarding Mylan’s offer to acquire Perrigo.

The Irish Takeover Panel cited three examples of Perrigo’s statements that could be misleading to shareholders.

The panel ruled that the statement “Mylan already proposed a dilutive deal that substantially undervalues Perrigo” breached Rule 19.3(a) as it was unclear that the term “dilutive” described the effect on Mylan shareholders as Mylan currently expects its proposed offer would be dilutive to its adjusted annual earnings per share for the first three years only following consummation of the offer and compulsory acquisition.

Next the second statement the panel ruled on was “Under Irish law, this structure all but guarantees that the promised synergy realization will fail.” This breached Rule 19.3(a) as merely dropping the acceptance condition to greater than 50% does not of itself mean that Mylan will not acquire 80% of the outstanding Perrigo shares pursuant to its offer without any consequential effects on Mylan’s projected synergies.

Finally, the panel ruled that the statement “we are confident that there is no rational path to a full acquisition of Perrigo” breached Rule 19.3(a) as the lowering of the acceptance condition to greater than 50% does not of itself mean that Mylan will not acquire 80% of the outstanding Perrigo shares pursuant to its offer.

Robert J. Coury, executive chairman of Mylan, stated:

Perrigo continues to make misleading comments with regard to Mylan’s offer to acquire Perrigo — comments which have unfortunately been inaccurately repeated by other third parties. The Irish Takeover Panel today has issued a formal statement noting in detail the inaccuracies in Perrigo’s public commentary. We are hopeful that today’s statements will provide Mylan and Perrigo shareholders with even greater confidence in Mylan’s previous statements with regard to the compelling nature of this transaction, our commitment to completing it, and our ability to realize the significant benefits from the combination, including the projected synergies, in order to create value for Mylan and Perrigo shareholders.

Shares of Mylan were up 2.7% to $51.14 on Tuesday afternoon. The stock has a consensus analyst price target of $67.00 and a 52-week trading range of $44.80 to $76.69.

Shares of Perrigo were up 1.7%, at $181.59 in its 52-week range of $135.00 to $215.73. The consensus price target is $210.20.

ALSO READ: Where Will Warren Buffett Put Money as Markets Collapse?

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.